 |
|
COMMENTS & OPINIONS
Treatment of MRSA Infections With Older Molecules: A Reasonable Option for Investigation—Reply
Annie Wong-Beringer, PharmD;
Levita K. Hidayat, PharmD;
Donald I. Hsu, PharmD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We are pleased to capture the attention of our colleagues and appreciate the opportunity to provide further discussions related to our prospective observational study examining the efficacy and safety of high-dose vancomycin therapy for the treatment of MRSA.1 Johnson requested definitions of "target" and "corrected" troughs used and an explanation of the outcome analysis performed in our study. Target trough was defined as achievement of an unbound vancomycin concentration at 4 to 5 times the MIC of the infected strain.1(p2139) Thus, for a strain with an MIC of 2 µg/mL and taking into account the 50% protein-binding property of vancomycin, attaining a target trough of 16 to 20 µg/mL is necessary to achieve 4 to 5 times the MIC of the infected strain, respectively (eg, bound + unbound drug concentration of 16 µg/mL = 2 µg/mL x 2 x 4). To . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED LETTER
Treatment of MRSA Infections With Older Molecules: A Reasonable Option for Investigation
Houssem Hmouda, Chaker Ben Salem, Kamel Bouraoui, and Letaief Jemni
Arch Intern Med. 2007;167(11):1207-1208.
EXTRACT
| FULL TEXT
RELATED ARTICLE
High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections: Efficacy and Toxicity
Levita K. Hidayat, Donald I. Hsu, Ryan Quist, Kimberly A. Shriner, and Annie Wong-Beringer
Arch Intern Med. 2006;166(19):2138-2144.
ABSTRACT
| FULL TEXT
|
